scispace - formally typeset
M

Michael Ittmann

Researcher at Baylor College of Medicine

Publications -  302
Citations -  35803

Michael Ittmann is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 81, co-authored 278 publications receiving 29888 citations. Previous affiliations of Michael Ittmann include National Institutes of Health & Harvard University.

Papers
More filters
Journal ArticleDOI

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, +311 more
- 05 Nov 2015 - 
TL;DR: The Cancer Genome Atlas (TCGA) has been used for a comprehensive molecular analysis of primary prostate carcinomas as discussed by the authors, revealing substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course.

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, +309 more
TL;DR: A comprehensive molecular analysis of 333 primary prostate carcinomas revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1).
Journal ArticleDOI

Pan-cancer analysis of whole genomes

Peter J. Campbell, +1332 more
- 06 Feb 2020 - 
TL;DR: The flagship paper of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium describes the generation of the integrative analyses of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types, the structures for international data sharing and standardized analyses, and the main scientific findings from across the consortium studies.
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.